Dow Jones Newswires Archives | Email alerts

June 27, 2022, 7:34 a.m. EDT

AstraZeneca-Daiichi Sankyo Enhertu breast cancer drug recommended for EU approval

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    AstraZeneca PLC (AZN)

or Cancel Already have a watchlist? Log In

By Jaime Llinares Taboada

AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.

The pharmaceutical company /zigman2/quotes/203048482/delayed UK:AZN -0.20% said Enhertu has been recommended by the EU’s Committee for Medicinal Products for Human Use as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

This decision was based on trial results showing that Enhertu reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.

Enhertu has been jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Co.

Write to Jaime Llinares Taboada at; @JaimeLlinaresT

UK : U.K.: London
10,946.00 p
-22.00 -0.20%
Volume: 220,757
Aug. 17, 2022 12:09p
P/E Ratio
Dividend Yield
Market Cap
£169.86 billion
Rev. per Employee

This Story has 0 Comments
Be the first to comment
More News In
Dow Jones Newswires

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.